Published in:
Open Access
01-12-2019 | SCLC | ASO Author Reflections
ASO Author Reflections: Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma
Authors:
Misaki Iijima, MD, PhD, Takehiko Yokobori, MD, PhD, Akira Mogi, MD, PhD, Ken Shirabe, MD, PhD, Hiroyuki Kuwano, MD, PhD
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2019
Login to get access
Excerpt
Lung combined neuroendocrine carcinomas (NECs) comprise NEC components such as small cell lung carcinoma (SCLC) or large cell NEC, and non-NEC components such as adenocarcinoma (ADC) or squamous cell carcinoma. Some researchers have reported that combined NECs have common epidermal growth factor receptor (EGFR) mutations in both NEC and non-NEC components,
1,
2 suggesting that these two components might originate from cells of the same origin. Interestingly, it has been reported that EGFR mutations are often observed in non-NECs, but are very rare in sporadic NECs, which almost always have p53 mutations.
3 Moreover, a case report showed that lung ADC with EGFR mutation transforms to SCLC as an NEC component in the process of acquiring EGFR-tyrosine kinase inhibitor (TKI) resistance.
4 Therefore, it was suggested that genetic and immunohistochemical analysis of EGFR and p53 for each component of combined NECs would provide important information on whether such components originate from the same tumor cells or incidentally arise as collision cancers. …
